Floatz logo

Benralizumab

Non-cystic Fibrosis Bronchiectasis

AstraZenecamonoclonal_antibodyPhase 3Dormant
C
37/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
81/ 100

Competitive context

22 Active assets in the Non-cystic Fibrosis Bronchiectasis cohort.

Asset / SponsorPhaseRating
Ciprofloxacin
Centre Hospitalier Intercommunal Creteil
Phase 4BBB
Azithromycin
Assiut University
Phase 4BBB
Lipitor
University of Edinburgh
Phase 4BB
Theophylline
The First Affiliated Hospital of Guangzhou Medical University
Phase 4BB
Roflumilast
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Benralizumab is also rated in:

bullous pemphigoidDormant
C
Indicative ·
37 / 100
View asset →
neoplasmDormant
C
Indicative ·
35 / 100
View asset →
carcinomaDormant
C
Indicative ·
35 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →